Fig. 2

Varevape single — study design. Exclusive daily EC users who intended to quit vaping were randomized to receive either varenicline, 1 mg, twice daily for 12 weeks or matched placebo for 12 weeks. Subjects were prospectively reviewed for up to 24 weeks during which vaping habits, questionnaire answers, adverse events, and vital signs were assessed at each visit. The telephone symbol indicates telephone contact